BMC Urology Urology

The double-decking method for rezūm water vapor therapy in benign prostatic hyperplasia: volumetric, functional, and dosimetric outcomes

Ming-Jui Tseng, Ka-Lun Lo, Chi-Hsiang Wu, Shih-Ying Lin, Chih-Jen Wang, Chen-Yueh Wen
Springer Nature · 2026-08-22 · DOI 10.1186/s12894-026-02329-5

Abstract

Abstract Background Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) significantly impact quality of life in aging men. Conventional Rezūm water vapor therapy consistently achieves only a modest 25–30% prostate volume reduction, leaving a clinically meaningful therapeutic gap—particularly for larger glands where single-plane periurethral injection fails to achieve adequate thermal coverage of the entire transition zone. Objectives To evaluate the efficacy and safety of a dual-layered injection strategy (“Double-decking method”) for Rezūm water vapor therapy, targeting a treatment cycles per unit prostate volume (CPV) > 0.15, in patients with symptomatic BPH. Design Retrospective analysis of a prospectively maintained database of consecutive patients treated at a single institution. Methods We enrolled 26 consecutive patients with symptomatic BPH (April 2025–December 2025) who underwent Rezūm therapy using the “Double-decking method,” in which two sequential injections were performed within each field-of-view—one targeting the anterior and one the posterior aspect of the transition zone—targeting a CPV > 0.15. The primary endpoint was prostate volume (PV) reduction at 3 months; secondary endpoints included IPSS, Qmax, post-void residual (PVR), ejaculatory function assessed by the MSHQ-EjD, and erectile function assessed by the IIEF-5. Results The mean CPV was 0.19. Total prostate volume decreased by 50.7% ( p < 0.001). Qmax improved by + 203.5% ( p < 0.001), PVR decreased by 95.2% ( p < 0.001), and IPSS declined by 77.2% ( p < 0.001). All 7 catheter-dependent patients achieved catheter independence. MSHQ-EjD scores showed a statistically significant but clinically non-meaningful decline at 3 months (− 1.4 points; p = 0.003), below the MCID of 3 points. IIEF-5 scores showed no significant change at 3 months (− 0.1 points; p = 0.705), with no change in ED severity distribution. Grade II adverse events occurred in 4 patients (15.4%); no Grade ≥ III complications were observed. Subgroup analysis demonstrated consistent PV reduction across all volume categories (47.9–53.2%), with a significant between-group difference in Qmax ( p = 0.013). A non-significant trend toward a plateau was observed beyond CPV ≈ 0.20. Conclusion In this single-centre cohort, the Double-decking method was associated with substantial prostate volume reduction and a favorable safety profile through optimized dual-layered CPV delivery. A therapeutic window of CPV 0.15–0.20 is proposed as a hypothesis-generating observation requiring prospective validation. Trial registration Not applicable (retrospective study).

Read at publisher →